Compare ELAN & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELAN | TECH |
|---|---|---|
| Founded | 1954 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 11.2B |
| IPO Year | 2018 | 1995 |
| Metric | ELAN | TECH |
|---|---|---|
| Price | $23.97 | $72.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $27.89 | ★ $71.82 |
| AVG Volume (30 Days) | ★ 7.5M | 3.2M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.62% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.22 | ★ 0.81 |
| Revenue | ★ $4,715,000,000.00 | $1,219,635,000.00 |
| Revenue This Year | $8.21 | $2.49 |
| Revenue Next Year | $5.31 | $6.40 |
| P/E Ratio | $107.09 | ★ $89.23 |
| Revenue Growth | ★ 6.22 | 5.23 |
| 52 Week Low | $17.11 | $43.20 |
| 52 Week High | $27.98 | $72.62 |
| Indicator | ELAN | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 67.75 |
| Support Level | $22.94 | $71.89 |
| Resistance Level | $25.67 | N/A |
| Average True Range (ATR) | 1.08 | 0.26 |
| MACD | 0.02 | -0.32 |
| Stochastic Oscillator | 41.82 | 58.22 |
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.